We know from multiple studies that we tend to overestimate AEs in patients treated in phase one trials and so we decided to actually implement PROs and remote monitoring in our patients in October 2024. What we were able to see is that we actually captured grade 3 and 4 adverse events before the DLT, which is pretty important because probably by implementing PROs in phase 1, we are going to better select the dose in the future, which is what we do in phase 1...
We know from multiple studies that we tend to overestimate AEs in patients treated in phase one trials and so we decided to actually implement PROs and remote monitoring in our patients in October 2024. What we were able to see is that we actually captured grade 3 and 4 adverse events before the DLT, which is pretty important because probably by implementing PROs in phase 1, we are going to better select the dose in the future, which is what we do in phase 1.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
